Wednesday - March 18, 2026

Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myotonic Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Myotonic Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading

Myopia Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Ziemer Group, NIDEK CO., LTD, 2EyesVision, Carl Zeiss AG, Alcon, CooperVision, Topcon Healthcare

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myopia pipeline constitutes 8+ key companies continuously working towards developing 10+ Myopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.   … Continue reading

Acute Kidney Injury Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Astellas Pharma, Amniotics, Guard Therapeutics, RegeneRx Biopharma, Cerenis

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Kidney Injury pipeline constitutes 30+ key companies continuously working towards developing 30+ Acute Kidney Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading